Arthroscopic microfracture with atelocollagen augmentation for osteochondral lesion of the talus: a multicenter randomized controlled trial

Table 2 Clinical Outcome Measures

	Preoperative^a	2-year follow-up^a	Difference^†	p-value^‡	p-value^§
100-mm VAS
Group 1	51.84 ± 19.98	17.25 ± 20.31	−34.59 (95% CI, −47.61 to −21.57)	< 0.001	0.72
Group 2	59.11 ± 19.67	19.37 ± 18.58	− 39.74 (95% CI, − 49.83 to − 29.64)	< 0.001
HSS
Group 1	68.82 ± 11.86	93.09 ± 13.64	24.27 (95% CI, 16.49 to 32.06)	< 0.001	0.14
Group 2	67.57 ± 14.74	86.09 ± 13.36	18.52 (95% CI, 11.19 to 25.86)	< 0.001
AOFAS
Group 1	72.23 ± 11.85	91.23 ± 8.62	19.00 (95% CI, 11.97 to 26.03)	< 0.001	0.09
Group 2	69.30 ± 17.97	86.91 ± 10.68	17.61 (95% CI, 9.02 to 26.20)	< 0.001

^aThe values are given as mean ± standard deviation. †The values are given as the mean and the 95% CI in parentheses. ‡p-values are calculated comparing the 2-year follow-up and preoperative values. §p-values are calculated comparing group 1 and group 2 values. Group 1 = experimental group (microfracture + atelocollagen augmentation), Group 2 = control group (microfracture alone), VAS visual analog scale, HSS Hannover scoring system, CI confidence interval; AOFAS American Orthopedic Foot and Ankle Society

ISSN: 1471-2474